Dynavax's stock rises 10% on expanded CEPI partnership

Shares of Dynavax Technologies Corp. /zigman2/quotes/203017054/composite DVAX +6.42% gained 10% in trading on Thursday after the company said it's making its adjuvant technology available to companies developing COVID-19 vaccines through a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), a not-for-profit organization in Oslo that has provided funding to a handful of vaccine developers in this pandemic. Dynavax's adjuvant technology can help provide an increased immune response to a vaccine; the biopharmaceutical company is also working with the University of Queensland, Australia, on vaccine development through a CEPI deal. GlaxoSmithKline /zigman2/quotes/209463850/composite GSK -0.81% , which is lending its adjuvant technology to COVID-19 vaccine development plans, has also partnered with CEPI, the University of Queensland, and Clover Biopharmaceuticals Inc., a Chinese biotechnology company, the same as Dynavax. Dynavax's stock is down 42% year-to-date. The S&P 500 /zigman2/quotes/210599714/realtime SPX +2.47% has dropped 23%.

/zigman2/quotes/203017054/composite

Add to watchlist DVAX

Dynavax Technologies Corp.

US : U.S.: Nasdaq

$ 12.43

+0.75 +6.42%

Volume: 3.02M

May 27, 2022 4:00p

P/E Ratio

16.25

Dividend Yield

N/A

Market Cap

$1.48 billion

Rev. per Employee

$1.50M

/zigman2/quotes/209463850/composite

Add to watchlist GSK

GSK PLC ADR

US : U.S.: NYSE

$ 44.06

-0.36 -0.81%

Volume: 5.74M

May 27, 2022 4:00p

P/E Ratio

15.98

Dividend Yield

4.54%

Market Cap

$111.59 billion

Rev. per Employee

$552,510

/zigman2/quotes/210599714/realtime

Add to watchlist SPX

S&P 500 Index

US : S&P US

4,158.24

+100.40 +2.47%

Volume: 2.17B

May 27, 2022 5:49p